|
ORENCIA (abatacept) is administered as a 30-minute intravenous
infusion every 4 weeks after initial dosing regimen
- ORENCIA is administered as a 30-minute intravenous infusion
at a fixed dose approximating 10 mg/kg throughout the course of treatment (see Table
for dosing)
- Dosing with ORENCIA remains fixed at 10 mg/kg throughout the
course of treatment.
- Following initial administration (Day 1), ORENCIA should be
given at Day 15 and Day 30 after the first infusion, then every 4 weeks thereafter.
Actual day of dosing may vary based on patient scheduling.
- ORENCIA should not be administered concomitantly with TNF antagonists.
ORENCIA is not recommended for use concomitantly with anakinra.
- ORENCIA does not require any premedication prior to infusions.
Appropriate medical support measures for the treatment of the hypersensitivity reactions
should be available for immediate use in the event of a reaction.
Adult Dosing Regimen
|
Body Weight of Patient* |
Dose
(mg) |
Number of Vials† |
Billable Units
(abatacept per 10 mg)‡ |
|
<60 kg (<132 lb) |
500 |
2 |
50 |
|
60 to 100 kg (132 to 220 lb) |
750 |
3 |
75 |
|
>100 kg (>220 lb) |
1000 |
4 |
100 |
JIA dosing is 10 mg/kg based on body weight at each visit and
not to exceed 1000 mg. Children aged 6 years and older weighing >75 kg should
follow the adult dosing schedule
*1 kg = 2.2 lb.
†Each vial provides 250 mg of abatacept for administration.
‡Permanent J code is J0129.
- Caution should be exercised in patients with a history of infection
or underlying conditions which predispose them to infections.
- In 5 clinical trials, less than 1% of patients treated with
ORENCIA experienced hypersensitivity reactions, including two cases of anaphylaxis
or anaphylactoid reactions.
- Live vaccines should not be given concurrently with ORENCIA
or within 3 months of its discontinuation.
It is recommended that JIA patients be brought up to date with all immunizations
in agreement with current immunization guidelines prior to initiating therapy with
ORENCIA.
NEXT: Preparation
|